RYVU Therapeutics S.A. — Share Issue/Capital Change 2022

Dec 2, 2022

Decisionto conduct public offering of J series shares in December 2022

The Management Board of RyvuTherapeutics S.A. with its registered office in Krakow, Poland(_quot;Issuer_quot;) informs that the Management Board of the Issueradopted on December 1, 2022 a resolution on its intent to conduct apublic offering of no more than 4,764,674 new Series J ordinary bearershares with a nominal value of PLN 0.40 (_quot;Series J Shares_quot;) in December2022.

Series J Shares are issued on thebasis of the resolution of the Management Board of the Company of 5October 2022, the adoption of which was announced in a current report No22/2022 of 5 October 2022.

The Management Board of theCompany aims to publish the prospectus drawn up in connection with thepublic offering of the J Series Shares and the intention to apply foradmission and introduction of the Series J Shares to trading on theregulated market (main market) of the Warsaw Stock Exchange S.A. (the_quot;Prospectus_quot;), promptly after the approval of the Prospectus by theFinancial Supervision Authority (Komisja Nadzoru Finansowego).

Terms of the public offering ofthe Series J Shares will be provided in the Prospectus.